Last updated: 2023/06/01
Homepage
Home
Services and Solutions
API Form and Solid-State Research
Solid Form Screening and Selection
Amorphous Solid Dispersions
Absolute Structure Determination
Crystallization Screening and Development
Chiral Separation by Crystallization
Solid-State Characterization (FAST)
Solid-State NMR Analysis
Pre-formulation Studies
Pre-formulation Study Package
Automated In-Vitro Testing
In-Silico PBPK Modeling and Simulation
Formulations for PK/Efficacy/Tox Studies
Formulation Development
Clinical and Commercial Manufacturing
Analytical Chemistry
Analytical Method Development and Validation
Drug Product Release
Stability Study
Compatibility Research
API-Excipient-Packaging Release
Mol2Med™ Developability Assessment
M4M™ Lead Op to FIH
Platforms
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
Conventional Oral Solid Dosage Forms
Formulation Development for Poorly Water-Soluble Drugs
Mini-Tablet
About Us
Our Company
Our History
Our People
Our Partner
Senior HR Specialist / HR Manager
Lab Specialist I
Resources
Company News
Industry Shift: FDA Goes Vegan?
Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving the Important Milestone in Formulation Capability
Crystal Pharmatech Returned to AAPS 2022 PharmSci 360
Crystal Pharmatech and Particle Sciences Form a US-China Pharmaceutical CRO Partnership
Crystal Pharmatech Raises $10 Million to Accelerate Growth
Crystal Formulation Services, Formulation Tailor-made for Your Molecules
Candoo Enables the Successful Development of a BCS 4 Combo Drug Product
International Company Crystal Pharmatech Finds CCIT An Optimal Spot for First US Location
Crystal Pharmatech Triples Headquarters in Biobay, China, with More Floors and Labs
Xceleron and Crystal Pharmatech Announce Partnership to Improve Early Clinical Development Utilizing Absolute Bioavailability Trials and Solid-State Solutions
Crystal Pharmatech Introduces Customized Service Packages for Customers Seeking Materials Science Approaches in Drug Discovery and Development
Crystal Pharmatech Expands Leadership Team
Crystal Formulation Services（CFS）Opens New Formulation Development Center and Analytical R&D Lab in Suzhou, China
Candoo's Formulation Technology Platform Featured in the Drug Development & Delivery Journal
Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion
Events
Crystal Pharmatech and the Future of Pharma at AAPS PharmSci 360
CPhI north america - Meet Us at Booth #530
Crystal Pharmatech Raring to Go to ChemOutsourcing 2022
Technical Articles
Case Studies
Case Study 1: Indinavir - Early Salt Form Change
Case Study 2: DPC 961 – Form Change On A Fast Track Compound
Case Study 3: Atorvastatin - Crystalline Form Change In Late Development
Case Study 4: Gatifloxacin - Crystalline Form Changes With A Licensed Compound
Case Study 5: Lifecycle Management - Olanzapine - Crystalline Change From Free Acid to Salt
Case Study 6: Oxybutynin- Crystalline Change From Salt to Free Base
Whitepaper
Amorphous Solid Dispersions
API Crystallization
Co-crystals
Impact of Solid-state in Early Development
Optimal Preclinical Formulation Development
Salts
Pharmaceutical Solid-state Forms
Classic Publications
Crystallization of Organic Compounds
Handbook of Industrial Crystallization (3rd Edition)
Polymorphism in Molecular Crystals
Polymorphism in Pharmaceutical Solids
Pharmaceutical Amorphous Solid Dispersions
Pharmaceutical Preformulation and Formulation
Webinar Series
Selecting the Right API Form and Formulation
Avoiding Drug Failures: Right First Time; Fast First Time
Tools and Strategies for De-risking Rapid Drug Substance and Drug Product Development
Advancements in Analytical Tools for API and DP Characterization
Solid Forms: The Good; The Bad; The Ugly
Utility of Single Crystal in Form and Formulation Selection
Introduction to MicroED Technology and Solutions
Formulation Implications
Molecules-to-Medicine: Accelerating Drug Development through Collaboration
The Purpose Behind Molecules to Medicine
Repurposing Dexmedetomidine into an Oral Sleep-Enhancing Medication
The Role of Collaboration in Optimizing the Development of HIF Inhibitors for the Treatment of Advan
Advanced Characterization: Tools for Accelerating Molecules to Medicine
The Tiny-TIM System
Detecting and Avoiding Disappearing Polymorph Cases by Crystal Structure Prediction
Instrumentation for Electron Diffraction, Applications, and Case Studies
PBPK in Preclinical/FIH Scenarios
Tools for Accessing New Solid Forms
Crystallization and Spray Drying Process Development, Scale-Up, and Technology Transfer
Exploring the Pharmaceutical Solid State by Molecular Simulation
Knowledge Hub
Learn about Drug Eutectic Screening
Crystallization Process Method
Fun Sharing: The Secret Behind the Silky Smoothness of Chocolate (Part 2)
Fun Sharing: The Secret behind the Silky Smooth Enjoyment of Chocolate (Part 3)
Fun Sharing: The Secret Behind the Silkiness of Chocolate (Part 1)
Fun Sharing：The Story Between Ice Crystals and Frozen Foods (Part 3)
Fun Sharing: The Relationship Between Ice Crystals and Frozen Foods (Part 1)
Fun Sharing: The Story of Ice Crystals and Frozen Foods (Part 2)
Presentations & Webinars
Solid Form Research
Engineering Cocrystal Solubility and Streamlining Cocrystal Early Development
Synthonic Engineering: Tools for the Rational Design of High Quality Pharmaceuticals
Effective Development of API Crystallization Processes During Drug Development
Using Thermodynamic Phase Maps in API Crystallization Process Design
Enabling Poorly Soluble Weak Bases for Improved Bioavailability: Why a Salt May Not be the Best Choice
Preclinical and Tox Formulation Development
The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C
Polymorphism of Drugs - Can We Exploit Physical Form in the Development of Low Solubility Molecules?
Efficient Preclinical Formulation Development for Poorly Soluble Compounds
Pre-clinical Formulation Strategies Sponsored by Crystal Pharmatech
Integrated Phase and Formulation Selection to Support GLP Toxicology and First in Human Studies Sponsored by Crystal Pharmatech
SMART Development of Pre-clinical Candidates
Careers
Talent Recruitment
Contact Us
Last updated: 2023/06/01
Homepage